Schering Settles Off-Label Promotion, Fraud Allegations For $435 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Settlement with Boston U.S. Attorney’s office includes amendment to Schering-Plough’s existing OIG corporate integrity agreement.
You may also be interested in...
Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges
Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs
Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges
Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs
Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million
Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.